# Sonoma Pharmaceuticals, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Sonoma Pharmaceuticals, Inc.).

## Overview

Sonoma Pharmaceuticals develops and sells stabilized hypochlorous acid (HOCl) products used in wound care, eye care, oral care, dermatology, podiatry, animal health care, and surface disinfection. The company operates through a U.S. parent with subsidiaries in Mexico and the Netherlands and sells through direct channels and partners in more than 55 countries.

## Products & services

• Stabilized hypochlorous acid (HOCl) wound care products
• Eye care products, including Acuicyn and Ocudox
• Dermatology products, including Celacyn, Levicyn, Epicyn, and Lasercyn
• Oral care, podiatry, and animal health care products
• Non-toxic disinfectants and hard-surface sanitizers

- **Wound care** (30%) — HOCl-based solutions and gels used for wound cleansing, irrigation, and skin protection.
- **Eye care** (15%) — Prescription and OTC products for eyelid, periocular, and blepharitis-related care.
- **Dermatology** (25%) — Products for acne, scar management, atopic dermatitis, and skin irritation.
- **Disinfectants and sanitizers** (15%) — Hard-surface disinfectant and sanitizer products sold through partners and distributors.
- **Animal health and other applications** (15%) — HOCl products used in veterinary and other specialized care applications.

- Stabilized hypochlorous acid (HOCl) wound care products
- Eye care products, including Acuicyn and Ocudox
- Dermatology products, including Celacyn, Levicyn, Epicyn, and Lasercyn
- Oral care, podiatry, and animal health care products
- Non-toxic disinfectants and hard-surface sanitizers

## Customers

Sonoma sells to distributors, retail partners, healthcare channels, and other commercial customers that market or use HOCl-based products. Its end markets include human healthcare, consumer health, veterinary care, and surface disinfection, with demand coming from both domestic and international buyers. The company also relies on a small number of customers that can represent a meaningful share of revenue in a given period.

- **Distributors and channel partners** (primary) — Buy HOCl products for resale across international and U.S. markets; important because Sonoma relies on partner-led commercialization.
- **Retail consumers via OTC channels** (primary) — Buy acne, wound care, and skin-care products through retailers and consumer health channels.
- **Healthcare professionals and clinics** (secondary) — Use prescription and professional-grade eye, wound, and dermatology products for patient care.
- **Veterinary and animal health customers** (secondary) — Buy HOCl-based products for animal care and related hygiene applications.
- **Surface disinfection customers** (secondary) — Buy hard-surface disinfectants and sanitizers through partners such as MicroSafe.

- Distributors that resell HOCl products in local markets
- Retail partners selling OTC acne and wound care products
- Healthcare channels using wound, eye, and dermatology products
- Animal health customers buying OTC veterinary products
- A small number of large customers can drive a significant share

## Geography

Sonoma has material international operations, with most revenue generated outside the United States and sales in over 55 countries. In the latest quarterly disclosures, Europe was the largest region, followed by the United States, Asia, Latin America, and the Rest of the World. The company also manufactures through its Mexico subsidiary and serves Europe through its Netherlands subsidiary.

- **United States** (26%) — Estimated from the nine months ended December 31, 2025 revenue mix.
- **Europe** (37%) — Estimated from the nine months ended December 31, 2025 revenue mix.
- **Asia** (18%) — Estimated from the nine months ended December 31, 2025 revenue mix.
- **Latin America** (12%) — Estimated from the nine months ended December 31, 2025 revenue mix.
- **Rest of the World** (7%) — Residual international markets not separately disclosed.

- United States is a major market for OTC and distributor-led sales
- Europe is a core region for wound, eye, acne, and disinfectant products
- Asia contributes meaningful revenue through larger but less frequent orders
- Latin America is exposed to timing of customer orders and manufacturing flow
- Mexico and the Netherlands support manufacturing and international operations

## Strategy

Sonoma's strategy centers on expanding distribution, securing regulatory clearances, and broadening the use of its HOCl platform across healthcare and consumer channels. It also seeks to deepen international reach, relaunch and extend product lines, and use partner-led commercialization to scale into new markets. The company continues to invest in product development and approvals to support market access and product breadth.

- **Expand partner-led distribution** (short-term) — The business depends on channel partners to reach retailers, healthcare buyers, and international markets.
- **Increase regulatory reach** (medium-term) — Approvals and clearances determine where HOCl products can be marketed and how broadly they can be sold.
- **Broaden product portfolio** (medium-term) — A wider product set supports cross-selling across wound care, dermatology, eye care, and consumer channels.
- **Grow international commercialization** (long-term) — International markets are a major revenue source and diversify demand beyond the U.S.

- Expand distribution through partners in the U.S. and abroad
- Use regulatory clearances to open new product indications and markets
- Broaden the HOCl platform across wound, eye, skin, and disinfectant uses
- Relaunch and extend consumer and prescription product lines
- Grow international sales through local approvals and channel partners

## Risks

Sonoma faces regulatory, quality, and commercialization risks because its HOCl products are sold in regulated healthcare and consumer categories across many countries. The company also depends on a small number of customers and third-party partners, which can create revenue volatility if demand shifts, approvals are delayed, or a partner underperforms. International exposure adds foreign exchange, tariff, and local compliance risk.

- **Regulatory non-compliance or delayed approvals** [high] — HOCl products require FDA and international clearances, and changes in labeling or quality systems can delay commercialization.
- **Dependence on third-party partners and contractors** [high] — The company relies on collaborators, suppliers, and distributors for manufacturing and market access.
- **Customer concentration** [high] — A small number of customers can account for a significant portion of revenue in a given year.
- **International operating risk** [medium] — Most revenue is generated outside the U.S., increasing exposure to currency, tariffs, and local regulation.
- **Product liability and recall risk** [high] — Healthcare and disinfectant products can face recalls, claims, or reputational damage if performance or labeling is challenged.

- FDA, EU, and local regulatory compliance can delay or block sales
- Third-party manufacturers and partners can disrupt supply or quality
- A few customers represent a large share of revenue in some periods
- International sales expose the company to FX, tariffs, and trade rules
- Product recalls or adverse publicity could damage brand trust

## Accounting

Key accounting judgments include revenue timing, customer concentration, inventory and receivable reserves, and valuation allowances on deferred tax assets. The company also notes estimates around equity transactions and financing-related items, while quarterly revenue can fluctuate because some international customers place larger, less frequent orders. These areas can materially affect reported results and comparability across periods.

- **Revenue recognition and channel timing** — Quarterly comparability and reported revenue
- **Allowance for doubtful accounts** — Net receivables and operating expense
- **Inventory reserves and write-downs** — Gross margin and inventory carrying value
- **Deferred tax asset valuation allowance** — Income tax expense and balance sheet assets
- **Equity financing and share-based transactions** — Share count, capital structure, and financing cash flows

- Revenue timing can vary by channel, geography, and order size
- Quarterly results can swing with large, infrequent international orders
- Receivable and inventory reserves require judgment and affect earnings
- Deferred tax asset valuation allowance reflects loss history and forecasts
- Equity issuance and financing accounting can affect share-based and capital items

---

*Last updated: 2026-04-29T04:59:33.132533+00:00*